Press Releases
Debiopharm mutualise son infrastructure de bornes de recharges pour les taxis électriques ou hybrides de Lausanne
MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s…
Genialis advances biomarker discovery to reduce risk in cancer drug development targeting DNA damage response pathways
Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea
Vulgaroo remporte le 9e Challenge qualité de vie du patient avec un prix de 25’000 francs suisse
CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections
Debiopharm to Showcase Research Results of Their First-In-Class Anti-Staphylococcal Program at IDWeek 2024 in Los Angeles
Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association